Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age […]
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety […]
Two years into the pandemic, health systems are still facing significant challenges in providing essential health services. Ongoing disruptions have been reported in over 90% […]
With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy […]
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies demonstrating that three doses of […]
WHO Director-General’s opening remarks at the media briefing on COVID-19 — 18 January 2022 The volcanic eruption near Tonga and subsequent tsunami requires an urgent […]
Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine […]
Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results […]
Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects […]
The future Spanish vaccine against covid, on which the Hipra laboratories based in Amer (Girona) are working, is showing good results against the omicron variant, […]
The Regional Ministry confirms that 1,127 people have been admitted to Valencian hospitals for covid and 178 to the ICU. The Comunitat Valenciana updates the […]
In Germany, the Paul-Ehrlich-Institut is the authority responsible for monitoring the safety of vaccines and biomedicines. For this purpose, the institute’s Division Pharmacovigilance collects and […]
– Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants – Third dose produced increased immune responses comparable to […]
The World Health Organization, with the support of the Strategic Advisory Group of Experts (SAGE) on Immunization and its COVID-19 Vaccines Working Group, continues to review the emerging evidence on the need for and […]
COVID-19 pandemic disrupts health services worldwide New evidence compiled by the World Health Organization and the World Bank shows that the COVID-19 pandemic is likely […]
Copyright © 2022 | WordPress Theme by MH Themes
